Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Genomic and Proteomic Study of Richter Syndrome

ID
Name
2017-A01978-45
Description
Biological study on Richter Syndrome (RS), an agressive lymphoma that arises from Chronic Lymphocytice Leukemia (CLL). RS presents with the same histological aspect as primitive Diffuse Large B-Cell Lymphoma (DLBCL), but is associated with a poor prognosis, due to chemorefractoriness. This study aims at understanding the biological determinants of chemotherapy resistance in Richter Syndrome.
Trial arms
Trial start
2017-09-06
Estimated PCD
2023-12-31
Trial end
2024-09-05
Status
Recruiting
Treatment
Whole exome sequencing.
Retrospective biological exploration of the samples, including tumoral DNA exploration.
Arms:
Control group with no tumor involvment of lymph nodes, Other secundary Diffuse Large B-Cell Lymphoma, Primitive Diffuse Large B-Cell Lymphoma, Richter Syndrom at diagnosis
RNA sequencing
Characterization of tumor transcriptomic profile.
Arms:
Control group with no tumor involvment of lymph nodes, Other secundary Diffuse Large B-Cell Lymphoma, Primitive Diffuse Large B-Cell Lymphoma, Richter Syndrom at diagnosis
Mass spectrometry
Characterization of tumor proteomic profiles.
Arms:
Control group with no tumor involvment of lymph nodes, Other secundary Diffuse Large B-Cell Lymphoma, Primitive Diffuse Large B-Cell Lymphoma, Richter Syndrom at diagnosis
Size
170
Primary endpoint
Whole exome sequencing data using next generation sequencing method
3 years
RNA sequencing data using next generation sequencing method
3 years
Proteomic analysis using mass spectrometry
3 years
Eligibility criteria
Inclusion Criteria: * Diagnosis of a Diffuse Large B-Cell Lymphoma arising in the context of a Chronic Lymphocytic Leukemia (group 1) or diagnosis of a primitive Diffuse Large B-Cell Lymphoma (group 2), or diagnosis of a Diffuse Large B-Cell Lymphoma arising in a context of small cells lymphoma, excluding CLL (group 3), or benefit from a diagnostic lymph node biopsy that did not reveal any tumor involvment (primitive or metastatic) (group 4). * Patients must benefit from a lymph node biopsy at diagnosis. * Patients must be followed by a FILO (French Innovative Leukemia Organization) member * Histology of Diffuse Large B-Cell Lymphoma or Hodgkin histology. * Suitable clinical data available. * Samples must meet the following requirement :RIN (RNA Integrity Number) \> 5 et DIN (DNA Integrity Number) \> 6.5. Exclusion Criteria: • Samples that do not meet the inclusion criteria (insufficient clinical data, analysis impossible due to insufficient sample quality).
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 170, 'type': 'ESTIMATED'}}
Updated at
2023-03-24

1 organization

2 products

1 indication

Organization
Central Hospital
Product
Whole exome sequencing
Indication
Richter syndrome
Product
RNA sequencing